Ont. government approves funding for ‘Butterfly Boy’ Johnathan Pitre’s 2nd stem cell transplant – CTV News
CTV News |
Ont. government approves funding for ‘Butterfly Boy’ Johnathan Pitre’s 2nd stem cell transplant
CTV News Some good news for the family of Jonathan Pitre. The Ontario government has approved funding for a second stem cell transplant for the local teenager. The 16-year-old from Russell, Ont. suffers from a blistering skin disease. |
|
Review: ‘Passengers’ under-performs its sizable budget
Daily American Online The travelers were eager enough for a new beginning that they abandoned all worldly friendships and associations, and submitted themselves to suspended animation, enforced hibernation, for the 120-year voyage to the distant Homestead II planet. |
Counsel & Heal |
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Yahoo Finance Roche Holding AG’s RHHBY Genentech announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients suffering from … FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder CancerCounsel & Heal |
Paris Post Intelligencer |
Local doctor first in area to do stem cell transplants
Paris Post Intelligencer The biggest advantage stem cell injections seem to offer over more invasive arthritis remedies is a quicker, easier recovery — the procedure is done on an outpatient basis, and the majority of patients are up and moving within only 24 hours with … |
Immuno-Oncology News |
Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
Immuno-Oncology News Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll … Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro’s CRS-207 With …Clinical Leader |
Community Financial News |
Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
Immuno-Oncology News Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll … Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro’s CRS-207 With …Clinical Leader |